molina healthcare inc. - MOH
MOH
Close Chg Chg %
286.26 -13.17 -4.60%
Pre-Market
273.09
-13.17 (4.60%)
Volume: 926.14K
Last Updated:
Feb 11, 2025, 3:59 PM EDT
Company Overview: molina healthcare inc. - MOH
MOH Key Data
Open $286.00 | Day Range 272.40 - 287.04 |
52 Week Range 272.40 - 423.92 | Market Cap $16.38B |
Shares Outstanding 57.20M | Public Float 56.50M |
Beta 0.54 | Rev. Per Employee N/A |
P/E Ratio 13.90 | EPS $16.04 |
Yield 0.00% | Dividend N/A |
EX-DIVIDEND DATE | SHORT INTEREST N/A |
AVERAGE VOLUME 707.97K |
MOH Performance
1 Week | -3.84% | ||
1 Month | -4.55% | ||
3 Months | -7.23% | ||
1 Year | -32.03% | ||
5 Years | 88.33% |
MOH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
18
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
Average Recommendation | OVERWEIGHT | Average Target Price | 341.643 | |
Number of Ratings | 18 | Current Quarters Estimate | 6.109 | |
FY Report Date | 03 / 2025 | Current Year's Estimate | 24.886 | |
Last Quarter’s Earnings | 5.05 | Median PE on CY Estimate | N/A | |
Year Ago Earnings | 22.65 | Next Fiscal Year Estimate | 28.339 | |
Median PE on Next FY Estimate | N/A |
Earnings Per Share
This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
---|---|---|---|---|
# of Estimates | 12 | 12 | 14 | 13 |
Mean Estimate | 6.11 | 6.39 | 24.89 | 28.34 |
High Estimates | 7.16 | 7.47 | 27.20 | 30.20 |
Low Estimate | 4.82 | 6.07 | 21.90 | 27.09 |
Coefficient of Variance | 8.62 | 6.13 | 5.23 | 3.32 |
Analysts Recommendations
Current | 1 Month Ago | 3 Months Ago | |
---|---|---|---|
BUY | 5 | 5 | 6 |
OVERWEIGHT | 2 | 2 | 2 |
HOLD | 10 | 10 | 9 |
UNDERWEIGHT | 1 | 1 | 1 |
SELL | 0 | 0 | 0 |
MEAN | Overweight | Overweight | Overweight |
SEC Filings for Molina Healthcare Inc. - MOH
Filing Date | Type | Category | Amended |
---|---|---|---|
No results |
Insider Actions for Molina Healthcare Inc. - MOH
Date | Name | Shares | Transaction | Value |
---|---|---|---|---|
Jul 3, 2024 | Daniel Cooperman Director | 5,977 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 1,746,240.32 |
Jul 3, 2024 | Jeff D. Barlow Chief Legal Officer | 71,488 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $252.71 per share | 18,065,732.48 |
Jul 3, 2024 | Stephen H. Lockhart Director | 2,442 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 713,454.72 |
Jul 3, 2024 | Ronna E. Romney Director | 17,133 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 5,005,577.28 |
Jul 3, 2024 | Richard M. Schapiro Director | 11,531 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 3,368,896.96 |
Jul 3, 2024 | Debra Bacon EVP, Medicaid | 6,689 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $252.71 per share | 1,690,377.19 |
Jul 3, 2024 | Debra Bacon EVP, Medicaid | 6,505 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $292.16 per share | 1,900,500.80 |
Jul 3, 2024 | Steven J. Orlando Director | 19,025 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 5,558,344.00 |
Jul 3, 2024 | Dale B. Wolf Director | 15,191 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 4,438,202.56 |
Jul 3, 2024 | Richard C. Zoretic Director | 6,647 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 1,941,987.52 |
Jul 3, 2024 | James E. Woys Chief Operating Officer | 53,682 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $252.71 per share | 13,565,978.22 |
Jul 3, 2024 | Barbara L. Brasier Director | 3,876 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $292.16 per share | 1,132,412.16 |
Mar 6, 2024 | Joseph M. Zubretsky President & CEO; Director | 333,217 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $387.21 per share | 129,024,954.57 |
Mar 6, 2024 | Joseph M. Zubretsky President & CEO; Director | 349,952 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $387.21 per share | 135,504,913.92 |
Mar 6, 2024 | Joseph M. Zubretsky President & CEO; Director | 360,591 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $387.21 per share | 139,624,441.11 |
Mar 6, 2024 | Joseph M. Zubretsky President & CEO; Director | 392,660 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $387.21 per share | 152,041,878.60 |
Mar 6, 2024 | Maurice S. Hebert Chief Accounting Officer | 10,058 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $387.21 per share | 3,894,558.18 |
Mar 6, 2024 | Maurice S. Hebert Chief Accounting Officer | 9,608 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $387.21 per share | 3,720,313.68 |
Mar 6, 2024 | James E. Woys Chief Operating Officer | 63,613 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $387.21 per share | 24,631,589.73 |
Mar 6, 2024 | James E. Woys Chief Operating Officer | 58,964 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $387.21 per share | 22,831,450.44 |